Christopher Peetz - 07 Aug 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
07 Aug 2025
Transactions value $
-$2,092,600
Form type
4
Filing time
08 Aug 2025, 16:49:31 UTC
Previous filing
18 Mar 2025
Next filing
12 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Peetz Christopher CHIEF EXECUTIVE OFFICER, Director C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 08 Aug 2025 0001614740

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $117K +40K +28.85% $2.94 179K 07 Aug 2025 Direct
transaction MIRM Common Stock Sale -$2.21M -40K -22.39% $55.25 139K 07 Aug 2025 Direct F1, F2
holding MIRM Common Stock 209K 07 Aug 2025 By The Peetz Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Employee Stock Option (right to buy) Options Exercise $0 -40K -16.77% $0.00 198K 07 Aug 2025 Common Stock 40K $2.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 22, 2024.
F2 The weighted average sale price for the transaction reported was $55.251022, and the range of prices were between $55.25 and $55.485. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The stock option is fully vested.